XML 58 R40.htm IDEA: XBRL DOCUMENT v3.25.1
Revenue Recognition (Tables)
 12 Months Ended
Dec. 31, 2024
Revenue from Contract with Customer [Abstract]  
Schedule of Contract Revenue Recognized
The following table provides the contract revenue recognized by revenue source for the years ended December 31, 2024 and 2023 (in thousands):

December 31,
20242023
Pharmaceutical Development Segment
License Agreement$49 $273 
Pharmaceutical development and other3,567 931 
Total contract revenue$3,616 $1,204 
Schedule of Contract with Customer Liability
The Company’s contract liabilities are presented as deferred income as of December 31, 2024 in the consolidated balance sheets (in thousands):

December 31,
2024
Pharmaceutical Development Segment
Balance at January 1, 2024
$9 
Income recognized(9)
Deferred income1,500 
Balance at December 31, 2024
$1,500